top of page

Making the case for allo durability at #ASCO23 with Allogene’s CEO

Allogene CEO David Chang describes the data his company presented at ASCO on Saturday and makes the case for the durability of the response.



Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page